Targeting ovarian cancer: Researcher finds disparities in access to the top-quality care that boosts survival

May 8, 2012
Dr. Robert Bristow, the Philip J. DiSaia Chair in Gynecologic Oncology and director of UC Irvine’s Division of Gynecologic Oncology, says poor and African American women have diminished chances of surviving ovarian cancer because of unequal access to newest treatment. Credit: Paul R. Kennedy

Dr. Robert Bristow believes a decidedly low-tech approach could significantly enhance the survival rate for ovarian cancer, even though it’s the deadliest women’s reproductive cancer, claiming 15,000 lives each year; it has no reliable screening or prevention methods; and its research funding is about one-sixth the amount for breast cancer.

“We don’t have to redesign a molecule to improve the outcome for women with ovarian cancer,” says Bristow, the Philip J. DiSaia Chair in and director of UC Irvine’s Division of Gynecologic Oncology. “Recent research has shown that the most profound impact on survivorship occurs when women get proper care from surgeons trained in the latest techniques for treating ovarian cancer.”

In March, he presented to the Society of Gynecologic Oncology a study of 50,000 ovarian cancer patients finding that poor women and African Americans were less likely to receive the highest standards of care, leading to worse outcomes than for white and affluent patients.

“Not all women are benefiting equally from improvements in ovarian ,” Bristow says. “The reasons behind these disparities are not entirely clear, which is why we need additional research.”

The study’s goal was to quantify differences related to race and socioeconomic status among women being treated for epithelial ovarian carcinomas – cancer that forms on the surface of an ovary. It also aimed to determine whether their care adhered to National Comprehensive Cancer Network treatment guidelines.

Bristow and colleagues found that five-year varied significantly. (Improvement in ovarian cancer care is measured in length of survival after diagnosis rather than a “cure” rate.)

Among those whose care met NCCN standards, the rate for white women was 41.4 percent, compared with 33.3 percent for African American women. Among those whose care did not meet NCCN standards, the rate for white women was 37.8 percent, compared with 22.5 percent for African American women. Those on Medicaid or without insurance faced a 30 percent increased risk of death. Poor women – defined as having an annual household income of less than $35,000 – had worse survival rates regardless of race.

Bristow’s study was part of an effort by the Society of Gynecologic Oncology and colleagues at the Mayo Clinic and Washington University in St. Louis to assess the quality and outcomes of ovarian cancer care in the U.S.

In November, Bristow led a symposium at UC Irvine that attracted gynecologic surgeons from 10 countries – including Australia, Poland and Denmark – to learn the latest surgical and chemotherapy techniques for treating ovarian cancer.

“This is helping us understand the kind of advanced expertise we need to bring to women in Denmark,” said Dr. Pernille Jensen of Odense University Hospital. Her nation is planning to consolidate ovarian cancer treatment from five sites to one in order to concentrate surgical expertise and improve the level of care women receive.

“There is a great need to raise the education level of fellowship-trained surgeons,” Bristow says. “Under the best circumstances, treating ovarian cancer is challenging, because there’s no screening tool available to detect the disease in its early stages.”

Since only 20 to 30 percent of ovarian cancers are diagnosed while still confined to the primary site, it’s critical that surgeons can effectively treat it in advanced stages after the cancer has spread to areas such as the liver, the lungs and nearby lymph nodes.

Even with late-stage can see survival rates significantly higher than those treated with traditional approaches.

“For example, we’ve known for several years that the combination of intravenous chemotherapy and intraperitoneal chemo – in which the drugs are injected directly into the abdominal cavity – greatly improves survival,” Bristow says. “Yet too many cancer centers rely solely on IV chemo.”

He says the symposium will become an annual event, with UC Irvine and colleagues at Washington University in St. Louis hosting in alternate years.

Explore further: Black women, uninsured get worse ovarian cancer care: study

More information: Clinical Gynecologic Oncology

Related Stories

Black women, uninsured get worse ovarian cancer care: study

March 27, 2012
(HealthDay) -- Women with ovarian cancer who are black, either uninsured or Medicare recipients, or who have annual incomes of less than $35,000 are more likely to receive poorer-quality care, a new study shows.

Potential for earlier diagnosis of ovarian cancer

January 25, 2012
(Medical Xpress) -- Australian scientists have identified biochemical changes that commonly occur in the DNA of women with ovarian cancer, which may help diagnose the cancer at an earlier stage in the future.

Evolving ovarian cancer cells 'dodge' treatment with chemotherapy

December 20, 2011
(Medical Xpress) -- Cancer Research UK scientists have discovered that the commonest type of ovarian cancer evolves at a startling rate, which may allow cancer cells to ‘dodge’ the current standard treatment, reveals ...

Experimental vaccine aimed at improving ovarian cancer survival rates

March 2, 2012
An experimental vaccine study currently under way at the UC Cancer Institute aims to prevent ovarian cancer recurrence by triggering the body’s natural defense system.

Recommended for you

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.